AU780136B2 - Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals - Google Patents
Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals Download PDFInfo
- Publication number
- AU780136B2 AU780136B2 AU24463/01A AU2446301A AU780136B2 AU 780136 B2 AU780136 B2 AU 780136B2 AU 24463/01 A AU24463/01 A AU 24463/01A AU 2446301 A AU2446301 A AU 2446301A AU 780136 B2 AU780136 B2 AU 780136B2
- Authority
- AU
- Australia
- Prior art keywords
- lipid
- suspension
- dry particles
- pharmaceutical
- delivery system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims description 34
- 239000003814 drug Substances 0.000 title claims description 30
- 239000007787 solid Substances 0.000 title description 9
- 150000002632 lipids Chemical class 0.000 claims description 102
- 239000002245 particle Substances 0.000 claims description 95
- 239000000725 suspension Substances 0.000 claims description 87
- 239000004094 surface-active agent Substances 0.000 claims description 41
- 239000007788 liquid Substances 0.000 claims description 32
- 238000002156 mixing Methods 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 239000000945 filler Substances 0.000 claims description 24
- 230000009974 thixotropic effect Effects 0.000 claims description 20
- 238000000465 moulding Methods 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 17
- 235000014121 butter Nutrition 0.000 claims description 14
- 239000000796 flavoring agent Substances 0.000 claims description 14
- 239000013029 homogenous suspension Substances 0.000 claims description 14
- 235000013311 vegetables Nutrition 0.000 claims description 14
- 238000002844 melting Methods 0.000 claims description 13
- 230000008018 melting Effects 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 11
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 11
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 11
- 239000008109 sodium starch glycolate Substances 0.000 claims description 11
- 239000005862 Whey Substances 0.000 claims description 10
- 102000007544 Whey Proteins Human genes 0.000 claims description 10
- 108010046377 Whey Proteins Proteins 0.000 claims description 10
- 239000007909 solid dosage form Substances 0.000 claims description 9
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 8
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 8
- 239000000787 lecithin Substances 0.000 claims description 8
- 235000010445 lecithin Nutrition 0.000 claims description 8
- 229940067606 lecithin Drugs 0.000 claims description 8
- 239000001856 Ethyl cellulose Substances 0.000 claims description 7
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 7
- 229920001249 ethyl cellulose Polymers 0.000 claims description 7
- 229940035676 analgesics Drugs 0.000 claims description 5
- 239000000730 antalgic agent Substances 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 5
- 229940088710 antibiotic agent Drugs 0.000 claims description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- 239000008141 laxative Substances 0.000 claims description 5
- 229940125722 laxative agent Drugs 0.000 claims description 5
- 238000002483 medication Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000007580 dry-mixing Methods 0.000 claims description 2
- 229940080313 sodium starch Drugs 0.000 claims description 2
- 239000012169 petroleum derived wax Substances 0.000 claims 2
- 235000019381 petroleum wax Nutrition 0.000 claims 2
- 235000019871 vegetable fat Nutrition 0.000 claims 2
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims 1
- 235000013351 cheese Nutrition 0.000 description 11
- 235000019634 flavors Nutrition 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 239000008188 pellet Substances 0.000 description 9
- 239000003925 fat Substances 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000005538 encapsulation Methods 0.000 description 6
- 239000003094 microcapsule Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 5
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 229940069428 antacid Drugs 0.000 description 5
- 239000003159 antacid agent Substances 0.000 description 5
- 230000001458 anti-acid effect Effects 0.000 description 5
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 5
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 5
- 229960003883 furosemide Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 5
- 229960005205 prednisolone Drugs 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 4
- 229960003184 carprofen Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 108010061435 Enalapril Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229960000309 enalapril maleate Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 229960003918 levothyroxine sodium Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000011361 granulated particle Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 229950008325 levothyroxine Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229940071117 starch glycolate Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003760 tallow Substances 0.000 description 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- IQUCNXSZNHPPML-UHFFFAOYSA-N 2-chloro-n-[(4-chlorophenyl)-phenylmethyl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C(NC(=O)CCl)C1=CC=CC=C1 IQUCNXSZNHPPML-UHFFFAOYSA-N 0.000 description 1
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 description 1
- WOKDXPHSIQRTJF-UHFFFAOYSA-N 3-[3-[3-[3-[3-[3-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)CO WOKDXPHSIQRTJF-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010012186 Delayed delivery Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- -1 carpofen Chemical compound 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- ZOMNIUBKTOKEHS-UHFFFAOYSA-L dimercury dichloride Chemical compound Cl[Hg][Hg]Cl ZOMNIUBKTOKEHS-UHFFFAOYSA-L 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- SSVFMICWXDVRQN-UHFFFAOYSA-N ethanol;sodium Chemical compound [Na].CCO SSVFMICWXDVRQN-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940038580 oat bran Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical class C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/476483 | 1999-12-30 | ||
| US09/476,483 US6340471B1 (en) | 1999-12-30 | 1999-12-30 | Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
| US09/656,297 US6541025B1 (en) | 1999-12-30 | 2000-09-06 | Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
| US09/656297 | 2000-09-06 | ||
| PCT/US2000/034776 WO2001049272A2 (en) | 1999-12-30 | 2000-12-20 | Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2446301A AU2446301A (en) | 2001-07-16 |
| AU780136B2 true AU780136B2 (en) | 2005-03-03 |
Family
ID=27045193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU24463/01A Ceased AU780136B2 (en) | 1999-12-30 | 2000-12-20 | Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6541025B1 (OSRAM) |
| EP (1) | EP1246615B1 (OSRAM) |
| JP (1) | JP2003523959A (OSRAM) |
| AU (1) | AU780136B2 (OSRAM) |
| CA (1) | CA2392621C (OSRAM) |
| WO (1) | WO2001049272A2 (OSRAM) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541025B1 (en) * | 1999-12-30 | 2003-04-01 | Shear/Kershman Laboratories, Inc. | Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
| MXPA03007337A (es) | 2001-02-15 | 2005-03-07 | King Pharmaceuticals Inc | Composicion farmaceutica y de hormona tiroidea estabilizada y metodo de preparacion de la misma. |
| FR2824477B1 (fr) * | 2001-05-09 | 2005-09-09 | Ethypharm Lab Prod Ethiques | Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'anfiotensine, leur procede de preparation et comprimes orodispersibles contenant les granules enrobes |
| US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
| SE0200154D0 (sv) * | 2002-01-21 | 2002-01-21 | Galenica Ab | New process |
| US20030190343A1 (en) * | 2002-03-05 | 2003-10-09 | Pfizer Inc. | Palatable pharmaceutical compositions for companion animals |
| CO5400144A1 (es) * | 2002-03-11 | 2004-05-31 | Novartis Ag | Compuestos organicos |
| US20040096498A1 (en) * | 2002-04-29 | 2004-05-20 | Alvin Kershman | Oral pharmaceutical delivery system with improved sustained release |
| US20030235613A1 (en) * | 2002-06-19 | 2003-12-25 | Cts Chemical Industries Ltd. | Popping oral administration form |
| EP1759692A3 (en) * | 2003-03-10 | 2007-09-12 | Novartis AG | Taste-masked solid veterinary compositions |
| US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
| US20070122488A1 (en) * | 2004-02-25 | 2007-05-31 | Erich Windhab | Multi-functional microcapsules and method and device for manufacturing same |
| US8075910B2 (en) * | 2004-05-20 | 2011-12-13 | Pbm Pharmaceuticals, Inc. | Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions |
| WO2006036624A2 (en) * | 2004-09-24 | 2006-04-06 | The Hartz Mountain Corporation | Lipid stabilized formulations |
| US20060142716A1 (en) * | 2004-12-29 | 2006-06-29 | Kimberly-Clark Worldwide, Inc. | Absorbent article featuring a non-abrasive temperature change member |
| US8129582B2 (en) * | 2004-12-29 | 2012-03-06 | Kimberly-Clark Worldwide, Inc. | Absorbent article featuring a temperature change member |
| US7956235B2 (en) * | 2004-12-29 | 2011-06-07 | Kimberly-Clark Worldwide, Inc. | Absorbent article featuring a temperature change member |
| US8318210B2 (en) | 2005-02-28 | 2012-11-27 | Neos Therapeutics, Lp | Compositions and methods of making sustained release liquid formulations |
| US8110226B2 (en) * | 2007-07-20 | 2012-02-07 | Mylan Pharmaceuticals Inc. | Drug formulations having inert sealed cores |
| US8486452B2 (en) * | 2007-07-20 | 2013-07-16 | Mylan Pharmaceuticals Inc. | Stabilized tolterodine tartrate formulations |
| GB0807605D0 (en) | 2008-04-28 | 2008-06-04 | Diurnal Ltd | Lipid composition |
| ES2569925T3 (es) * | 2009-09-30 | 2016-05-13 | Acura Pharmaceuticals, Inc. | Métodos y composiciones de disuasión del abuso |
| EP2838516B1 (en) | 2012-04-18 | 2018-10-17 | SpecGx LLC | Immediate release, abuse deterrent pharmaceutical compositions |
| WO2014011830A1 (en) | 2012-07-12 | 2014-01-16 | Mallinckrodt Llc | Extended release, abuse deterrent pharmaceutical compositions |
| EP2890367A4 (en) * | 2012-08-29 | 2016-03-30 | Salix Pharmaceuticals Inc | REMEDY COMPOSITION AND METHOD FOR TREATING CONSTELLATION AND RELATED DISEASES AND SUFFERING THE STOMACH DARM TRAKT |
| JP5922851B2 (ja) | 2012-11-30 | 2016-05-24 | アキュラ・ファーマシューティカルズ・インコーポレーテッド | 活性医薬成分の自己制御放出 |
| FR3002736B1 (fr) | 2013-03-04 | 2015-06-26 | Virbac | Composition orale nutritionnelle et medicamenteuse a usage veterinaire |
| FR3002735B1 (fr) | 2013-03-04 | 2015-07-03 | Virbac | Composition orale nutritionnelle et medicamenteuse a usage veterinaire |
| US10420729B2 (en) | 2013-03-15 | 2019-09-24 | R.P. Scherer Technologies, Llc | Abuse resistant capsule |
| BR112015021002B8 (pt) | 2013-03-15 | 2023-03-28 | Mallinckrodt Llc | Forma de dosagem sólida farmacêutica compreendendo um ingrediente farmacêutico ativo |
| AU2015237721B2 (en) | 2014-03-26 | 2018-04-26 | Sun Pharma Advanced Research Company Ltd. | Abuse deterrent immediate release coated reservoir solid dosage form |
| WO2016004170A1 (en) | 2014-07-03 | 2016-01-07 | Mallinckrodt Llc | Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides |
| US9155704B1 (en) * | 2014-07-13 | 2015-10-13 | Jugal K. Taneja | More palatable, bioequivalent pharmaceutical composition of carprofen |
| WO2017040607A1 (en) | 2015-08-31 | 2017-03-09 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
| US11478426B2 (en) | 2018-09-25 | 2022-10-25 | SpecGx LLC | Abuse deterrent immediate release capsule dosage forms |
| AU2021216630A1 (en) | 2020-02-05 | 2022-09-22 | Neurocrine UK Limited | Testosterone containing pharmaceutical composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4581381A (en) * | 1983-11-14 | 1986-04-08 | Nabisco Brands, Inc. | Soft homogeneous antacid tablet |
| US4749575A (en) * | 1983-10-03 | 1988-06-07 | Bio-Dar Ltd. | Microencapsulated medicament in sweet matrix |
| WO1999014712A1 (en) * | 1997-09-16 | 1999-03-25 | Snk Corporation | Apparatus for preparing reproduced image, method of preparation and reproduced image |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2238973A (en) | 1940-07-26 | 1941-04-22 | American Cyanamid Co | Sulphonamide compound in oil |
| US3238103A (en) | 1961-04-26 | 1966-03-01 | Clarence A Vogenthaler | Therapeutic composition and method of making it |
| US3253988A (en) | 1962-11-20 | 1966-05-31 | Robert I Pearlman | Antacid composition and method of using same |
| DE1482489A1 (de) | 1965-01-13 | 1970-03-12 | Boehringer Mannheim Gmbh | Vollautomatisches Dragierverfahren |
| US3843778A (en) | 1970-04-28 | 1974-10-22 | Rorer Inc William H | Antacids |
| US4327076A (en) | 1980-11-17 | 1982-04-27 | Life Savers, Inc. | Compressed chewable antacid tablet and method for forming same |
| SE8404808L (sv) * | 1983-10-03 | 1985-04-04 | Avner Rotman | Mikrokapslat lekemedel i sot matris |
| US4981690A (en) | 1987-10-27 | 1991-01-01 | Board Of Regents, The University Of Texas System | Liposome-incorporated mepartricin |
| US5032404A (en) | 1989-02-23 | 1991-07-16 | Board Of Regents, The University Of Texas System | Lipsome-incorporation of polyenes |
| US5229131A (en) * | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
| JPH06501354A (ja) * | 1990-10-09 | 1994-02-10 | スタージェ・アコムパニー・ベスローテン・フェンノートシャップ | 冷却装置を備えたダイナミックラウドスピーカ |
| US5175002A (en) | 1991-10-02 | 1992-12-29 | Du Pont Merck Pharmaceutical Company | Amantadine hydrochloride syspension with enhanced dissolution characteristics for use in soft gelatin capsules |
| ES2107685T3 (es) * | 1992-10-16 | 1997-12-01 | Glaxo Group Ltd | Composiciones de ranitidina que enmascaran su sabor. |
| GR1001437B (el) | 1992-11-05 | 1993-12-30 | Aggelos Kontos | Ζαχαροπλαστικό σύστημα χορηγήσεως φαρμακολογικώς δραστικών ουσιών. |
| US5576016A (en) | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
| JPH07242568A (ja) * | 1994-03-04 | 1995-09-19 | Eisai Co Ltd | 苦味隠蔽製剤 |
| US5567439A (en) * | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
| TW442287B (en) * | 1995-06-13 | 2001-06-23 | American Home Produits Corp | Organoleptically acceptable oral pharmaceutical composition comprising the S(+)1,8-diethyl-1-1,3,4,9-tetrahydropyrano[3,4-b] indole-1-acetic acid (Etodolac) |
| GR1002668B (el) | 1996-03-15 | 1997-04-14 | N | Μεθοδος προσθηκης στειρου αεριου αζωτου και φαρμακολογικως δραστικων ουσιων εις στερεο γιαουρτι. |
| AU728526B2 (en) * | 1997-02-14 | 2001-01-11 | Smithkline Beecham Corporation | Pharmaceutical formulations comprising amoxocyllin and clavulanate |
| US6241997B1 (en) | 1998-03-16 | 2001-06-05 | Smtm Group. Llc | Chewable calcium supplement and method |
| US6221857B1 (en) * | 1998-06-10 | 2001-04-24 | North Carolina State University | Altering sex ratio of offspring in mammals |
| US6340471B1 (en) * | 1999-12-30 | 2002-01-22 | Alvin Kershman | Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
| US6541025B1 (en) * | 1999-12-30 | 2003-04-01 | Shear/Kershman Laboratories, Inc. | Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
| US20050123596A1 (en) * | 2003-09-23 | 2005-06-09 | Kohane Daniel S. | pH-triggered microparticles |
-
2000
- 2000-09-06 US US09/656,297 patent/US6541025B1/en not_active Expired - Lifetime
- 2000-12-20 JP JP2001549640A patent/JP2003523959A/ja active Pending
- 2000-12-20 WO PCT/US2000/034776 patent/WO2001049272A2/en not_active Ceased
- 2000-12-20 CA CA2392621A patent/CA2392621C/en not_active Expired - Lifetime
- 2000-12-20 EP EP00988234A patent/EP1246615B1/en not_active Expired - Lifetime
- 2000-12-20 AU AU24463/01A patent/AU780136B2/en not_active Ceased
-
2006
- 2006-07-21 US US11/490,594 patent/US20070026066A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4749575A (en) * | 1983-10-03 | 1988-06-07 | Bio-Dar Ltd. | Microencapsulated medicament in sweet matrix |
| US4581381A (en) * | 1983-11-14 | 1986-04-08 | Nabisco Brands, Inc. | Soft homogeneous antacid tablet |
| WO1999014712A1 (en) * | 1997-09-16 | 1999-03-25 | Snk Corporation | Apparatus for preparing reproduced image, method of preparation and reproduced image |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001049272A2 (en) | 2001-07-12 |
| CA2392621A1 (en) | 2001-07-12 |
| EP1246615A2 (en) | 2002-10-09 |
| AU2446301A (en) | 2001-07-16 |
| CA2392621C (en) | 2010-11-02 |
| US20070026066A1 (en) | 2007-02-01 |
| EP1246615B1 (en) | 2010-04-21 |
| JP2003523959A (ja) | 2003-08-12 |
| US6541025B1 (en) | 2003-04-01 |
| WO2001049272A3 (en) | 2002-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU780136B2 (en) | Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals | |
| US6340471B1 (en) | Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals | |
| AU2003285189B2 (en) | Oral testosterone delivery system with improved sustained release | |
| EP2167049B1 (en) | Tamper resistant lipid-based oral dosage form for opioid agonists | |
| AU2012345726B2 (en) | Amphipathic lipid-based sustained release compositions | |
| AU2009289464B2 (en) | Chewable sustained release formulations | |
| US20050136121A1 (en) | Oral peptide delivery system with improved bioavailability | |
| JP2005538128A (ja) | ペット用のおいしい制御放出処方物 | |
| US8420700B1 (en) | Tamper resistant lipid-based oral dosage form for sympathomimetic amines | |
| US20080305177A1 (en) | Method of administering testosterone | |
| US20040096498A1 (en) | Oral pharmaceutical delivery system with improved sustained release | |
| US10722458B2 (en) | Amphipathic lipid-based sustained release compositions | |
| US20190000766A1 (en) | Abuse deterrent soft chewable drug formulations |